Skip to main content
. 2016 Jan 28;16:44. doi: 10.1186/s12885-016-2081-z

Table 3.

Number and stage of patients in the Post-EBUS cohort (N = 326) who had EBUS

EBUS-GS group EBUS-TBNA group
Stage (n) n (%a) n (%a)
NSCLC
 I (55) 9 (16.4) 6 (10.9)
 II (23) 4 (17.4) 2 (8.7)
 III (75) 9 (12.0) 23 (30.7)
 IV (135) 12 (8.9) 21 (15.6)
SCLC
 Limited (18) 0 (0) 8 (44.4)
 Extensive (20) 0 (0) 2 (10.0)
 Overall (326) 34 (10.4)b 62 (19.0)b

aPercentage within cancer stage

bIncludes 6 patients who had both EBUS-GS and EBUS-TBNA